Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP784711.RAQbWFkQDXn-YLjZ0k5UHS_PxI3r5SSuqFQf7_mKyeOuk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP784711.RAQbWFkQDXn-YLjZ0k5UHS_PxI3r5SSuqFQf7_mKyeOuk130_assertion type Assertion NP784711.RAQbWFkQDXn-YLjZ0k5UHS_PxI3r5SSuqFQf7_mKyeOuk130_head.
- NP784711.RAQbWFkQDXn-YLjZ0k5UHS_PxI3r5SSuqFQf7_mKyeOuk130_assertion description "[In order to define a useful TSP for targeting in the context of melanoma gene therapy, four promoters, the cyclooxygenase-2 (Cox-2), alpha-chemokine SDF-1 receptor (CXCR4), epithelial glycoprotein 2 (EGP-2), and survivin, were tested in both established melanoma cell lines and primary melanoma cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP784711.RAQbWFkQDXn-YLjZ0k5UHS_PxI3r5SSuqFQf7_mKyeOuk130_provenance.
- NP784711.RAQbWFkQDXn-YLjZ0k5UHS_PxI3r5SSuqFQf7_mKyeOuk130_assertion evidence source_evidence_literature NP784711.RAQbWFkQDXn-YLjZ0k5UHS_PxI3r5SSuqFQf7_mKyeOuk130_provenance.
- NP784711.RAQbWFkQDXn-YLjZ0k5UHS_PxI3r5SSuqFQf7_mKyeOuk130_assertion SIO_000772 15696177 NP784711.RAQbWFkQDXn-YLjZ0k5UHS_PxI3r5SSuqFQf7_mKyeOuk130_provenance.
- NP784711.RAQbWFkQDXn-YLjZ0k5UHS_PxI3r5SSuqFQf7_mKyeOuk130_assertion wasDerivedFrom befree-20150227 NP784711.RAQbWFkQDXn-YLjZ0k5UHS_PxI3r5SSuqFQf7_mKyeOuk130_provenance.
- NP784711.RAQbWFkQDXn-YLjZ0k5UHS_PxI3r5SSuqFQf7_mKyeOuk130_assertion wasGeneratedBy ECO_0000203 NP784711.RAQbWFkQDXn-YLjZ0k5UHS_PxI3r5SSuqFQf7_mKyeOuk130_provenance.